Additionally, the proportion of fibroblasts showed an increasing trend after two cycles of therapy in responders, while no significant difference was found in non-responders.
← all excerpts
De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trial.
2
—
—
The sentences
S1c ), the proportion of cancer cells and pDCs demonstrated a decreasing trend after treatment in responders compared to pretreatment levels while no significant difference was found in non-responders.